Navigation Links
Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases

Additional data to be published in an upcoming issue of Anti-Cancer Drugs

VANCOUVER, March 20 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today announced that two peer-reviewed publications will feature Protox's PRX 302. The Journal of the National Cancer Institute ("JNCI") has published the work conducted by Dr. Sam Denmeade and his team at Johns Hopkins University in collaboration with Protox scientists. The paper describes the Company's compound, PRX302, which is a prostate specific antigen (PSA) activated pro-drug being developed for the treatment of prostate cancer and BPH.

"Having results of our PRX302 research program published in a prestigious journal such as JNCI is a testament to the importance of advancing PRX302 for prostate cancer and BPH," stated Dr. Fahar Merchant, President and CEO of Protox. "The published results are consistent with the encouraging interim data from the ongoing Phase I prostate cancer trial reported earlier this year and supports the planned Phase I BPH clinical trial which we expect to commence in Q2 of 2007."

The major advantage of using PRX302 as a therapeutic agent for prostatic diseases is that it involves direct injection into the target tissue and selective activation by PSA produced only by the target tissue. The paper, entitled "A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease" (JNCI, Vol.99, Issue 5 pp, 376-385) found that: PRX302 direct injection into the prostate did not cause any attributable accumulation of PRX302 outside of the prostate gland; is not toxic to adjacent non-PSA producing organs and tissues; and PRX302 has a selective mechanism of action and favourable safety profile.

A second paper entitled, "Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity" is to appear in the upcoming issue of Anti-Cancer Drugs (ACD). The journal will publish the work cond
'"/>




Page: 1 2 3

Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/30/2015)... Company, Inc. (NYSE: LCI ) today announced that ... Annual Growth Conference on Wednesday, August 12, 2015, at ... A webcast of the presentation will be ... visit the web site at least 10 minutes prior ... and install any necessary software.  The presentation will be ...
(Date:7/30/2015)... -- Flexpoint Ford, a private equity firm focused on ... it has entered into a partnership with Alan ... Kastle Therapeutics, LLC (Kastle).  The new company, headquartered in ... developing and commercializing pharmaceuticals targeted toward diseases with high ... already approved for marketing, as well as clinical assets ...
(Date:7/30/2015)... 30, 2015   HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are ... announced total revenue of $73.6 million for the ... million for the quarter ended June 30, 2014. ... million, or nine percentage points, during the three ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14
(Date:7/30/2015)... ... 30, 2015 , ... In a meaningful ritual intended to symbolize a final ... Center have created an addiction graveyard. Sharing this with the public comes at a ... Rocky Hudson . Hudson (1945-2015) fell in love with the desert when he moved ...
(Date:7/30/2015)... Diego, CA (PRWEB) , ... July 30, 2015 ... ... has been consistently growing into one of the largest, family-owned low cost service ... across residential and commercial applications, as well as growing their company to meet ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility ... effort to provide comfort to patients as well as visiting friends and family during ... phone charging stations. , The stations - powered by ChargeItSpot , a Philadelphia-based ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research Foundation ... Registry Act of 2015’. The bill was introduced in Congress yesterday by Representatives ... McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of the ...
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd Clay ... taxpayer money to fund the state’s large prison system, which has amassed largely enough ... rates of incarceration. In light of President Obama’s recent reduction of non violent drug ...
Breaking Medicine News(10 mins):Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3
... decades, hip replacement surgery has been the only treatment for ... younger patients may replace the traditional replacements.// ,Bobby Castor ... in grade school led to a condition called avascular necrosis. ... the hips drive a golf swing, it hurt Castor’s game. ...
... Laboratory research has found evidence that the venom that ... beneficial effects // on some heart problems, strokes, central ... involved the experimental drug ziconotide, a laboratory-made equivalent of ... Magus cone snail, which lives in shallow tropical saltwater. ...
... IGF-1 will increase substantially risks of breast, colon and ... hormone is a disaster waiting to happen. They say ... -- increases levels of insulin-like growth factor 1 (IGF-1). ... can do. ,Currently, human growth hormone is ...
... the drug gabapentin (Neurontin) taken at 2,400 milligrams ... for people with chronic daily headaches. ,Gabapentin is ... its success in treating other pain-related health issues ... Since gabapentin often reduces migraines by more than ...
... analyzed results from a questionnaire that included more than 4,400 ... the annual British Household Panel Survey, began in 1991. Results ... health, but marriage is better for a woman's . ,Researchers ... work out reported much poorer mental health than men who ...
... drug that strongly activates certain systems in the brain.// ... is often addictive. According to the 2000 National Household ... the United States have tried methamphetamine at least once ... methamphetamine users and 18 healthy people to determine how ...
Cached Medicine News:
Optical Urethrotome 8667 for telescope 4 mm, 0. For slitting urethral strictures under vision...
OES Pro Optical Urethrotome...
... With a 4.9mm insertion tube, ... and increases maneuverability even through strictured ... wide viewing angle of 125 in ... a large viewing area and simplifying ...
New technology in optics, processing and application. Laser-welded mechanics in stainless steel provide high safety in sterilization. Saphire windows distal and proximal, validated even for autoclavi...
Medicine Products: